Application of ProTide Technology to Gemcitabine: A Successful Approach to Overcome the Key Cancer Resistance Mechanisms Leads to a New Agent (NUC-1031) in Clinical DevelopmentMagdalena Ślusarczyk, Christopher McGuigan, Monica Huerta Lopez et al.|Journal of Medicinal Chemistry|2014Cited by 151
Anti-tumour activity of a first-in-class agent NUC-1031 in patients with advanced cancer: results of a phase I studySarah P. Blagden, Essam Ghazaly, Ivana Rizzuto et al.|British Journal of Cancer|2018Cited by 43
A Phase Ib Open-Label, Dose-Escalation Study of NUC-1031 in Combination with Carboplatin for Recurrent Ovarian CancerFarasat Kazmi, Sarah P. Blagden, Shibani Nicum et al.|Clinical Cancer Research|2021Cited by 10
Abstract B46: NUC-3373: A novel pyrimidine nucleotide analogue that overcomes key cancer drug resistance limiting patient survivalEssam Ghazaly, Sarah P. Blagden, Magdalena Ślusarczyk et al.|Molecular Cancer Therapeutics|2015Cited by 9
ProGem1: Phase I first-in-human study of the novel nucleotide NUC-1031 in adult patients with advanced solid tumors.Essam Ghazaly, Sarah P. Blagden, Oluwadunni E. Emiloju et al.|Journal of Clinical Oncology|2013Cited by 8